These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18391999)

  • 41. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I studies in Spain: involvement of the multinational industry.
    Alcaide A
    Methods Find Exp Clin Pharmacol; 1999; 21 Suppl B():37. PubMed ID: 10599046
    [No Abstract]   [Full Text] [Related]  

  • 43. J&J's billion dollar punt on anti-amyloid antibody.
    Sheridan C
    Nat Biotechnol; 2009 Aug; 27(8):679-81. PubMed ID: 19668155
    [No Abstract]   [Full Text] [Related]  

  • 44. Liquid refreshment.
    Scott C
    Nat Biotechnol; 2013 Feb; 31(2):115. PubMed ID: 23392506
    [No Abstract]   [Full Text] [Related]  

  • 45. Osteoporosis: overview and pipeline.
    Yasothan U; Kar S
    Nat Rev Drug Discov; 2008 Sep; 7(9):725-6. PubMed ID: 19172687
    [No Abstract]   [Full Text] [Related]  

  • 46. What's fueling the biotech engine-2012 to 2013.
    Aggarwal RS
    Nat Biotechnol; 2014 Jan; 32(1):32-9. PubMed ID: 24406926
    [No Abstract]   [Full Text] [Related]  

  • 47. Acquisitions not a cure for anti-infectives.
    Bradley D
    Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178116
    [No Abstract]   [Full Text] [Related]  

  • 48. Trial watch : Progress for Phase III cancer vaccines.
    Nat Rev Drug Discov; 2008 Dec; 7(12):966-7. PubMed ID: 19043443
    [No Abstract]   [Full Text] [Related]  

  • 49. Industry shifts focus to immunology and cancer.
    Ledford H
    Nature; 2008 Nov; 456(7218):6. PubMed ID: 19004069
    [No Abstract]   [Full Text] [Related]  

  • 50. Which are the antibodies to watch in 2012?
    Reichert JM
    MAbs; 2012; 4(1):1-3. PubMed ID: 22327425
    [No Abstract]   [Full Text] [Related]  

  • 51. A testing approach based on tiny doses still awaits big results.
    Coombs A
    Nat Med; 2008 Aug; 14(8):796. PubMed ID: 18685584
    [No Abstract]   [Full Text] [Related]  

  • 52. Market watch: Sales of biologics to show robust growth through to 2013.
    Goodman M
    Nat Rev Drug Discov; 2009 Nov; 8(11):837. PubMed ID: 19876035
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure.
    Mullard A
    Nat Rev Drug Discov; 2016 Aug; 15(9):591-592. PubMed ID: 27573221
    [No Abstract]   [Full Text] [Related]  

  • 54. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 55. Cabilly patent finale.
    Waltz E
    Nat Biotechnol; 2008 Aug; 26(8):846. PubMed ID: 18688222
    [No Abstract]   [Full Text] [Related]  

  • 56. Bedside to bench: betting on B cells in multiple sclerosis.
    Link H
    Nat Med; 2008 Jun; 14(6):615-6. PubMed ID: 18535578
    [No Abstract]   [Full Text] [Related]  

  • 57. When the party's over.
    Wadman M
    Nature; 2007 Jan; 445(7123):13. PubMed ID: 17203035
    [No Abstract]   [Full Text] [Related]  

  • 58. New relief for gout.
    Adams JU
    Nat Biotechnol; 2009 Apr; 27(4):309-11. PubMed ID: 19352359
    [No Abstract]   [Full Text] [Related]  

  • 59. Antivirals--an increasingly healthy investment.
    McCarthy B
    Nat Biotechnol; 2007 Dec; 25(12):1390-3. PubMed ID: 18066033
    [No Abstract]   [Full Text] [Related]  

  • 60. Nanobodies.
    Gibbs WW
    Sci Am; 2005 Aug; 293(2):78-83. PubMed ID: 16053141
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.